acebilustat

01/01/2018 - "EMPIRE-CF: A phase II randomized placebo-controlled trial of once-daily, oral acebilustat in adult patients with cystic fibrosis - Study design and patient demographics."
01/01/2017 - "The results of this study support further clinical development of acebilustat for treatment of cystic fibrosis."
01/01/2017 - "Acebilustat is a new once-daily oral antiinflammatory drug in development for treatment of cystic fibrosis (CF) and other diseases. "
01/01/2017 - "Seventeen patients with mild to moderate cystic fibrosis were enrolled and randomized into groups receiving placebo or doses of 50 mg or 100 mg acebilustat administered orally, once daily for 15 days. "
11/01/2021 - "Empire-CF study: A phase 2 clinical trial of leukotriene A4 hydrolase inhibitor acebilustat in adult subjects with cystic fibrosis."

01/01/2023 - "Acebilustat, a leukotriene B4 inhibitor, has potential to reduce inflammation and symptom duration. "
01/01/2020 - "Other treatments including azithromycin and acebilustat may dampen Aspergillus-induced inflammation due to their immunomodulatory properties. "
01/01/2017 - "The aim of this study was to evaluate the safety of acebilustat, a leukotriene A4 hydrolase inhibitor, and its effect on inflammation biomarkers in patients with cystic fibrosis. "

11/01/2021 - "We report findings from a randomized placebo-controlled trial of acebilustat in adult subjects with mild-to-moderate lung disease. "

01/01/2023 - "Evaluation of Acebilustat, a Selective Inhibitor of Leukotriene B4 Biosynthesis, for Treatment of Outpatients With Mild-Moderate Coronavirus Disease 2019: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial."
01/01/2023 - "Despite this, leukotriene B4 antagonism with acebilustat did not shorten symptom duration in outpatients with COVID-19. "